Corvus Pharmaceuticals, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Research and development | $33.7M | $19.4M | $16.5M | $24.5M | $29.1M |
| Operating expenses | $43.0M | $27.5M | $23.4M | $32.6M | $38.6M |
| Operating income | -$43.0M | -$27.5M | -$23.4M | -$32.6M | -$38.6M |
| Pretax income | -$13.3M | -$59.1M | -$21.7M | -$31.3M | -$43.2M |
| Income tax expense | $0 | $0 | $0 | $0 | $0 |
| Net income | -$15.3M | -$62.3M | -$27.0M | -$41.3M | -$43.2M |
| Balance Sheet | |||||
| Cash and equivalents | $4.6M | $8.7M | $12.6M | $13.2M | $63.5M |
| Current assets | $58.2M | $54.4M | $28.0M | $43.7M | $71.3M |
| Total assets | $71.1M | $68.9M | $45.6M | $68.2M | $109.5M |
| Current liabilities | $9.4M | $35.4M | $6.9M | $10.8M | $9.7M |
| Total liabilities | $9.9M | $36.3M | $6.9M | $12.1M | $12.3M |
| Stockholders' equity | $61.2M | $32.6M | $38.7M | $56.1M | $97.2M |
| Cash Flow Statement | |||||
| Cash from operations | -$32.8M | -$25.4M | -$23.9M | -$27.0M | -$36.7M |
| Depreciation and amortization | $105,000 | $85,000 | $151,000 | $367,000 | $460,000 |
| Stock-based compensation | $5.3M | $3.0M | $2.1M | $2.7M | $4.2M |
| Capital expenditure | $174,000 | — | $34,000 | $269,000 | $5,000 |
| Free cash flow | -$33.0M | — | -$24.0M | -$27.3M | -$36.7M |
| Dividends paid | $0 | $0 | $0 | $0 | $0 |
Shares outstanding 84.1M · Free float 64.3%
Annual filing data through FY ended December 31, 2025; float as of July 14, 2026.